மார்கரெட் க்ருேன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மார்கரெட் க்ருேன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மார்கரெட் க்ருேன் Today - Breaking & Trending Today

Pets and pain: NCSU study seeks to unravel link between breeds, sensitivity


RALEIGH – Deep down, pet owners know it. Veterinarians do, too.
There’s the bulldog who seems tougher than other breeds and the pug who’s a little more squeamish than others. There’s the golden retriever who is as happy-go-lucky as only golden retrievers can be, even when in pain.
What’s unknown is if there is actual science behind the perceptions.
A new study at the NC State College of Veterinary Medicine is hoping to be the first to answer an intriguing and potentially impactful question: Are there actual breed differences when it comes to pain sensitivity?
“We’re trying to pinpoint whether it’s just a stereotype that we carry around or if there is something to it,” says Margaret Gruen, CVM assistant professor of behavioral medicine, who is overseeing the research project. “If there is this biological basis for a difference in pain sensitivity, that would be something important for us to know from the standpoint of treatment of dogs, but al ....

United States , Bonnie Giles , Duncan Lascelles , Rachael Cunningham , Jack Russell , Margaret Gruen , American Kennel Club , National Institutes Of Health , Drug Administration , Duke University , College Of Veterinary Medicine , State College , Veterinary Medicine , Rachel Park , Brian Hare , Animals Workshop , National Institutes , Kenneth Royal , Michigan State University , ஒன்றுபட்டது மாநிலங்களில் , போனி கில்ஸ் , டங்கன் ல்யாஸல்ஸ் , ரேசல் கன்னிங்ஹாம் , பலா ரஸ்ஸல் , மார்கரெட் க்ருேன் , அமெரிக்கன் கெநெல் சங்கம் ,

Zoetis Receives European Commission Marketing Authorization for Solensia® (frunevetmab), a New Therapy for Feline Osteoarthritis Pain


Share:
Solensia is the first injectable monoclonal antibody (mAb) licensed for alleviation of pain associated with osteoarthritis (OA) in cats
Solensia works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain
European Commission Marketing Authorization for a similar product in dogs, Librela
®,
was received in November 2020
Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia
® (frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition
1, existing in 40% of cats, and may generate pain and limit a cat s comfort and quality of life if not treated. ....

Catherine Knupp , Margarete Gruen , Mike Mcfarland , Rob Kelly , Clin Pharmacokinet , Zoetis Veterinarian Market Research , European Commission Marketing Authorization , European Commission , Zoetis Inc , International Operations At Zoetis , Nerve Growth Factor , Commission Marketing Authorization , Executive Vice President , Assistant Professor , Behavioral Medicine , North Carolina State University , Chief Medical Officer , International Operations , Looking Statements , Annual Report , Factors That May Affect Future , Quarterly Reports , Current Reports , Veterinarian Market Research , Project November , கேத்தரின் க்னுபப் ,

Zoetis Inc.: Zoetis Receives European Commission Marketing Authorization for Solensia (frunevetmab), a New Therapy for Feline Osteoarthritis Pain


Zoetis Inc.: Zoetis Receives European Commission Marketing Authorization for Solensia (frunevetmab), a New Therapy for Feline Osteoarthritis Pain
Solensia works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain
European Commission Marketing Authorization for a similar product in dogs, Librela
,
was received in November 2020
Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia
(frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition
1, existing in 40% of cats, and may generate pain and limit a cat s comfort and quality of life if not treated. ....

Catherine Knupp , Margarete Gruen , Mike Mcfarland , Rob Kelly , Bill Price , Clin Pharmacokinet , Zoetis Veterinarian Market Research , European Commission Marketing Authorization , European Commission , Zoetis Inc , International Operations At Zoetis , Nerve Growth Factor , Commission Marketing Authorization , Executive Vice President , Assistant Professor , Behavioral Medicine , North Carolina State University , Chief Medical Officer , International Operations , Looking Statements , Annual Report , Factors That May Affect Future , Quarterly Reports , Current Reports , Veterinarian Market Research , Project November ,